GlaxoSmithKline (GSK)'s Melanoma Cocktail Slows Cancer in Study
5/18/2012 6:35:02 AM
GlaxoSmithKline Plc (GSK)’s combination of two experimental melanoma medicines slowed the progress of cancer with few skin complications in an early study, suggesting the combo may not have as many side effects as existing single- drug treatments.
Patients taking Glaxo’s dabrafenib and trametinib together had a lower incidence of rash and skin lesions than previously reported with Roche’s Zelboraf, according to a study of 77 patients with advanced melanoma, the most-severe form of skin cancer. The study, funded by London-based Glaxo, was released yesterday ahead of the American Society of Clinical Oncology meeting that begins June 1 in Chicago.
comments powered by